{"id":"keverprazan-10-days","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Hypotension"},{"rate":"5-10%","effect":"Increased urination"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, keverprazan reduces glucose reabsorption in the kidneys, leading to a decrease in blood glucose levels. This mechanism of action is primarily used to treat type 2 diabetes mellitus.","oneSentence":"Keverprazan is a selective and reversible inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:11.764Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06734260","phase":"PHASE3","title":"Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Eighth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-09-10","conditions":"Helicobacter Pylori Eradication Rate","enrollment":477},{"nctId":"NCT07122024","phase":"PHASE4","title":"Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-02-19","conditions":"Helicobacter Pylori","enrollment":414}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Amoxicillin"],"phase":"marketed","status":"active","brandName":"Keverprazan 10 days","genericName":"Keverprazan 10 days","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Keverprazan is a selective and reversible inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}